This Article Full Text Full Text (PDF) Correction (v112,pe126) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davidson, M. H. Search for Related Content PubMed PubMed Citation Articles by Davidson, M. H. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Statins Related Collections Risk Factors Hypertension - basic studies Clinical Studies Lipid and lipoprotein metabolism Related Article

(Circulation. 2005;111:2280-2281.)
© 2005 American Heart Association, Inc.

Editorial

Clinical Significance of Statin Pleiotropic Effects

Hypotheses Versus Evidence

Michael H. Davidson, MD

From Radiant Research; Preventive Cardiology, Rush University Medical Center; and Department of Medicine, Rush Medical College, Chicago, Ill.

Correspondence to Michael H. Davidson, MD, 515 N State St, Suite 2700, Chicago, IL 60610. E-mail michaeldavidson@radiantresearch.com

Key Words: Editorials • statins • lipoproteins • trials • coronary disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The word "pleiotropic" usually is applied to genetics, referring to the multiple actions of a single gene. Regarding drug therapy for dyslipidemia, however, the term has become synonymous with clinical benefits beyond the effects of the drug on lipoproteins. HMG-CoA reductase inhibitors (statins), as the most widely prescribed drugs in the world, have been extensively evaluated for effects independent of lipid alterations. Mice and rats are relatively good models to evaluate potential pleiotropic effects of HMG-CoA reductase inhibitors because statins do not lower circulating cholesterol concentrations in these species. Statin administration results in greater nitric oxide bioavailability, increased ability to recruit endothelial progenitor cells, inhibition of cardiac hypertrophy, and reductions in the size and severity of strokes.¹ Despite a failure to lower blood cholesterol, however, these drugs may influence cell membrane lipid levels. In rodent models, statins have been shown to decrease mitogen-activated protein kinase activation, enhance nitric oxide synthase expression, and reduce LOX-1 transcription by reducing oxidized low-density lipoprotein (LDL) uptake in endothelial cell membranes.² Accordingly, the pleiotropic effects in animals may not be independent of the cellular uptake of lipids.

See p 2356

In humans, the purported clinical benefits of statins have ranged from improved bone density to reduced occurrence of Alzheimer disease, as well as enhanced cardiovascular benefits beyond blood lipid modification. Numerous studies have demonstrated that statins improve endothelial function, most likely by increasing nitric oxide bioavailability and reducing oxidant stress. Statins also may have "negative pleiotropic" effects because they may downregulate cholesterol efflux from nonloaded . . . [Full Text of this Article]

Related Article:

Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans

Ulf Landmesser, Ferdinand Bahlmann, Maja Mueller, Stephan Spiekermann, Nina Kirchhoff, Svenja Schulz, Costantina Manes, Dieter Fischer, Kirsten de Groot, Danilo Fliser, Günter Fauler, Winfried März, and Helmut Drexler
Circulation 2005 111: 2356-2363. [Abstract] [Full Text]

This article has been cited by other articles:

				Y. Fang, K. Imagawa, X. Zhou, A. Kita, R. Sugiura, W. Jaiseng, and T. Kuno Pleiotropic phenotypes caused by an opal nonsense mutation in an essential gene encoding HMG-CoA reductase in fission yeast Genes Cells, June 1, 2009; 14(6): 759 - 771. [Abstract] [Full Text] [PDF]

				F. Antonini-Canterin, E. Leiballi, R. Enache, B. A. Popescu, M. Rosca, E. Cervesato, R. Piazza, C. Ginghina, and G. L. Nicolosi Hydroxymethylglutaryl Coenzyme-A Reductase Inhibitors Delay the Progression of Rheumatic Aortic Valve Stenosis: A Long-Term Echocardiographic Study J. Am. Coll. Cardiol., May 19, 2009; 53(20): 1874 - 1879. [Abstract] [Full Text] [PDF]

				E. A. Stein Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease Mayo Clin. Proc., April 1, 2009; 84(4): 307 - 309. [Full Text] [PDF]

				M. H. DAVIDSON Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications Cleveland Clinic Journal of Medicine, July 1, 2008; 75(7): 479 - 496. [Full Text] [PDF]

				P. A Howard and B. J Barnes Potential Use of Statins to Prevent Atrial Fibrillation After Coronary Artery Bypass Surgery Ann. Pharmacother., February 1, 2008; 42(2): 253 - 258. [Abstract] [Full Text] [PDF]

				B. Belay, P. F. Belamarich, and C. Tom-Revzon The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions Pediatrics, February 1, 2007; 119(2): 370 - 380. [Abstract] [Full Text] [PDF]

				C H Strey, J M Young, J H Lainchbury, C M Frampton, M G Nicholls, A M Richards, and R S Scott Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure Heart, November 1, 2006; 92(11): 1603 - 1609. [Abstract] [Full Text] [PDF]

				S. C. Smith Jr Can preventive therapy alter the initial presentation of coronary heart disease? Ann Intern Med, February 21, 2006; 144(4): 296 - 297. [Full Text] [PDF]

				L. G. Futterman and L. Lemberg The Expanding Role of the HMG-CoA Reductase Inhibitor, The Most Widely Prescribed Drug in the World Am. J. Crit. Care., November 1, 2005; 14(6): 555 - 558. [Full Text] [PDF]